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Background: Excision repair cross-complementing group 2 (ERCC2) plays important roles in the repair of DNA
damage and adducts. Single nucleotide polymorphisms (SNPs) of ERCC2 gene are suspected to influence the risks
of oral cancer. We performed a meta-analysis to systematically summarize the possible association of ERCC2
rs1799793 and rs13181 polymorphisms with oral cancer risks.
Methods: We retrieved the relevant articles from PubMed and Embase databases. Studies were selected using
specific criteria. ORs and 95% CIs were calculated to assess the association. All analyses were performed using the
Stata software.
Results: Six studies were included in this meta-analysis. There were no significant associations between ERCC2
rs1799793 and rs13181 polymorphism with overall oral cancer risk. In the stratified analysis by ethnicity, no significant
associations were found. In the stratified analysis by tumor type, the risk of oral leukoplakia was significant associated
with rs13181 polymorphism (AC vs. AA: OR = 1.28, 95% CI = 1.01-1.62, P = 0.546 for heterogeneity, I2 = 0.0%; CC vs. AA:
OR = 1.94, 95% CI = 0.99-3.79, P = 0.057 for heterogeneity, I2 = 60.1%; dominant model AC + CC vs. AA: OR = 1.35,
95% CI = 1.08–1.69, P = 0.303 for heterogeneity, I2 = 17.6%; allele C vs. A: OR = 1.38, 95% CI = 1.04–1.82. P = 0.043
for heterogeneity, I2 = 56.4%).
Conclusion: Rs13181 in ERCC2 gene might be associated with oral leukoplakia risk.Background
An estimated 263,900 new cases and 128,000 deaths from
oral cavity cancer (including lip cancer) occurred in 2008
worldwide [1]. Its increasing incidence and mortality rates
during the last two decades pose a big challenge to scien-
tists and doctors. A review highlighted the strength of the
association of several of the risk factors (e.g., tobacco and
alcohol use, and diet) related to oral and pharyngeal can-
cers [2]. Early premalignant oral lesions, such as leukopla-
kia, appear as a white patch in the oral cavity of chewing
and tobacco smoking, and five to ten percent of them pro-
gress to malignancy [3]. Therefore, the identification of
biomarkers for screening the high-risk individuals for* Correspondence: luli@mail.cmu.edu.cn
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reproduction in any medium, provided the orincreased predisposition to cancer is very important for
prevention of cancer.
Environmental carcinogens contained in air pollution
or tobacco smoking fumes, which are suggested to be
important risk factors for oral cancer, could cause many
types of DNA damages such as forming DNA adducts,
cross-links and unrepaired DNA damage can result in cell
apoptosis or unregulated cell growth and may eventually
lead to cancer. The various DNA repair pathways play im-
portant roles in the genomic stability, thus defending
against carcinogenesis. Individuals with suboptimal
DNA repair capacity are at increased risk of smoking-
related cancers, such as lung cancer and squamous cell
carcinoma of the head and neck [4,5]. There has been
increasing evidence that DNA damage plays a critical
role in the carcinogenesis of most cancers and DNA re-
pair genes are considered key genes associated with the
onset of cancer [6-8]. There are at least four pathwaysLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Tobacco-induced DNA adducts are primarily removed
by nucleotide excision repair (NER) pathway. The vari-
ation in DNA repair capacity may due to the single nu-
cleotide polymorphisms (SNP) in DNA repair genes. So
it is of utmost importance to investigate the SNPs in
genes involved in NER pathway to understand the eti-
ology of oral cancer.
Excision repair cross-complimentary group 2 (ERCC2)
is an important DNA repair gene in NER pathway. ERCC2
is located in chromosome 19q13.2-13.3 and codes for
an evolutionarily conserved helicase, a subunit of TFIIH
complex, which is essential for NER. SNPs in exons of
DNA repair genes may influence their protein activity,
resulting in differences of individual NER and DNA repair
capacity that may affect the susceptibility of diseases. The
common polymorphisms in exons of ERCC2 gene is at
codon 751 (A > C substitution at nucleotide position
35931, exon 23, Lys > Gln, rs13181) and codon 312 (G > A
substitution at position 23951, exon 10, Asp > Asn,
rs1799793). To date, there are studies reporting the
association between polymorphisms of ERCC2 codon
312 and 751with oral cancer risk but these published
data were contradictory [10-15]. Until now, there was
no meta-analysis or systematic review on the risk of
oral cancer with ERCC2 polymorphism. So we perform
an updated meta-analysis on all available case–control
studies to assess the oral cancer risk with rs13181 and
rs1799793 in ERCC2 gene.
Methods
Data sources
We retrieved the articles using the following terms
“Excision repair cross-complimentary group 2 or ERCC2
or Xeroderma pigmentosum D or XPD” and “oral cancer
or oral carcinoma” from PubMed and Embase (Last
search was updated on May 2013). We evaluated poten-
tially relevant publications by examining their titles and
abstracts and all studies matching the eligible criteria
were retrieved.
Study selection and data extraction
Eligible studies were selected according to the following
explicit inclusion criteria: (a) evaluation of the rs13181
and/or rs1799793 polymorphism and oral cancer or oral
leukoplakia risks, (b) using the methodology of a case–
control study. (c) There was sufficient published data for
the computation of odds ratios (ORs) with 95% confi-
dence intervals (95% CIs), for example there are number
of cases and controls with different genotypes or alleles
in published paper to calculate ORs and their 95% CIs.
Duplicate and obviously unrelated articles were elimi-
nated by a single author (E.Z.). Abstracts of the remaining
articles were examined independently by two authors(E.Z. and Z.C.) to determine whether the full-text article
should be sought. The following information was ob-
tained from each publication: first author’s name, publi-
cation year, country origin, ethnicity, case characteristics,
total number of cases and controls, and numbers of each
group with rs13181 and rs1799793 genotypes, respectively.
Statistical methods
We first assessed Hardy-Weinberg equilibrium using
Chi-square test in control groups for each included study.
ORs and their 95% CIs were calculated to evaluate the
association between ERCC2 SNPs and cancer risks. Pooled
ORs were calculated from combination of each study by
heterozygote comparison (GA vs. GG for rs1799793; AC
vs. AA for rs13181), homozygote comparison (AA vs.
GG for rs1799793; CC vs. AA for rs13181), dominant
model (GA + AA vs. GG for rs1799793; AC + CC vs. AA
for rs13181), recessive model (AA vs. GA + GG for
rs1799793; CC vs. AC +AA for rsrs13181) and allelic
model (A vs. G for rs1799793; C vs. A for rs13181) respect-
ively. For each genetic comparison model, subgroup ana-
lysis according to ethnicity was investigated to estimate
ethnic-specific ORs for Asian population, but not for
Caucasian population because there was only one paper
in Caucasians. Meanwhile stratified analyses by tumor
type were also applied for each genetic comparison model.
Values of Akaike’s Information Criterion (AIC) are re-
ported for model comparison, with the best models show-
ing the smallest AIC [16].
We assessed the between-study heterogeneity by
Cochran’s Q test and quantified by I2 (a significance
level of P < 0.10 and/or I2 ≥ 50%). If the P value is >0.05
of the Q test, the summary OR estimate of each study
was calculated by the fixed-effect model. Otherwise, the
random-effect model was used. The effect of publication
bias was examined by inverted funnel plots and the
Egger’s test. The significance of the intercept was deter-
mined by the t test as suggested by Egger’s test. All of
P values were two-sided and all analyses were performed
using the Stata software version 11.0 (Stata Corp, College
station, TX).
Results
Characteristics of included studies
According to these criteria, a total of 17 articles were
eligible. One study of review, two studies on cancer
prognosis and three studies about cell line were excluded.
Five studies were excluded because of no cancer risk and
data missing. Finally 6 articles were included and used
in quantitative synthesis for systematic review [10-15].
Flow chart of the study selection process was shown in
Figure 1.
The characteristics of selected studies are summarized
in Table 1. There were one study of European and five
Figure 1 Flow chart of the study selection process.
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rs1799793 SNP, including 742 cases and 738 controls.
There were 1202 cases and 1145 controls in 6 studies
for ERCC2 rs13181 SNP. Among three studies of ERCC2
rs1799793 polymorphisms, one study included the asso-
ciation between this polymorphism with oral cancer risk
and all of the three studies contain the association be-
tween the polymorphism and oral leukoplakia risk. For
rs13181 polymorphism, data sets about the risk of oral
cancer and oral leukoplakia were both four. The poly-
merase chain reaction–restriction fragment length poly-
morphism (PCR-RFLP) method was the most common
technique used for analyzing the genotype frequencies
of the two SNPs. The distributions of genotypes in the
controls were all in Hardy-Weinberg equilibrium (HWE).
ERCC2 rs1799793 SNP
The A allele frequency of the ERCC2 rs1799793 poly-
morphism among the controls across different ethnicities
ranged from 0.26 to 0.30. The average A allele frequenciesin Asian and Caucasians populations were 27.0 and 30.0%,
respectively. Heterogeneity between studies was not
observed so the fixed-effect model was conducted. The
overall ORs with its 95% CIs didn’t show statistically
association between rs1799793 polymorphism and oral
cancer risk (GA vs. GG: OR = 1.14, 95% CI = 0.91-1.43,
P = 0.182 for heterogeneity, I2 = 41.2%; AA vs. GG: OR =
1.27, 95% CI = 0.87-1.86, P = 0.436 for heterogeneity,
I2 = 0%; dominant model GA +AA vs. GG: OR = 1.16,
95% CI = 0.94-1.44, P = 0.268 for heterogeneity, I2 =
24.0%; recessive model AA vs. GA + GG: OR = 1.18, 95%
CI = 0.82-1.70, P = 0.406 for heterogeneity, I2 = 0%;
allele A vs. G: OR = 1.13, 95% CI = 0.96–1.34, P = 0.491
for heterogeneity, I2 = 0%) (Table 2). Because there was
only one study among Caucasian population and one
study on oral squamous cell cancer, the stratified ana-
lyses were not conducted in rs1799793 polymorphism.
No publication bias was detected by either the inverted
funnel plot or Egger’s test. The shapes of the funnel plot
for the comparison of the G allelic and the A allelic of
Table 1 Characteristics of all studies in meta-analysis















India Asian 39.0 ± 13.0/39.0 ± 13.0 60/6 60/2 Rs1799793 OL 66/62 23 13 4 23 21 1 0.13
Rs13181 OL 66/62 26 20 10 29 23 2 0.32
Wang Y (2007) [11] America Caucasian 58.3 ± 12.8/59.7 ± 11.0 81/63 162/126 Rs1799793 OL 144/288 50 59 16 140 109 29 0.26
Rs13181 OL 144/288 46 77 21 120 132 28 0.34
Majumder M
(2007) [12]
India Asian 49.0 ± 11.9/47.0 ± 10.3 196/28 302/87 Rs1799793 OL 224/388 117 89 18 205 146 36 0.18
OSCC 308/388 152 119 34 205 146 36 0.18
Total 532/388 269 208 52 205 146 36 0.18
Rs13181 OL 224/388 105 98 21 190 158 40 0.40
OSCC 308/388 158 125 26 190 158 40 0.40
Total 532/388 263 223 47 190 158 40 0.40
Kietthubthew S
(2006) [13]
Thailand Asian 67.1/68.4 77/29 91/73 Rs13181 OSCC 112/192 83 21 1 126 36 2 0.75
Bau DT (2007) [14] China Asian 53.0 ± 10.1/ 54.4 ± 12.1 None None Rs13181 OC 154/105 134 18 2 89 15 1 0.68
Ramachandran S
(2006) [15]
India Asian None None None Rs13181 OC 110/110 49 46 15 71 31 8 0.09
OL 84/110 41 29 14 71 31 8 0.09
Total 194/110 90 75 29 71 31 8 0.09
OL: Oral leukoplakia, OSCC: Oral squamous cell cancer, OC: oral cancer.

















Table 2 Association between ERCC2 polymorphisms with oral cancer risks
No of studies Fixed-effect Random-effect Phet I-squared (%)
Rs1799793
GA vs. GG 3 1.14[0.91,1.43] 1.13[0.80,1.61] 0.182 41.2
AA vs. GG 3 1.27[0.87,1.86] 1.24[0.87,1.85] 0.436 0.0
GA + AA vs. GG 3 1.16[0.94,1.44] 1.17[0.89,1.55] 0.268 24.0
AA vs. GA + GG 3 1.18[0.82,1.70] 1.16[0.81,1.68] 0.406 0.0
A vs. G 3 1.13[0.96,1.34] 1.13[0.96,1.34] 0.491 0.0
Rs13181
AC vs. AA 6 1.16[0.96,1.40] 1.17[0.90,1.51] 0.171 35.5
CC vs. AA 6 1.42[1.03,1.96] 1.71[0.92,3.20] 0.044 56.1
AC + CC vs. AA 6 1.19[1.00,1.43] 1.24[0.92,1.67] 0.045 55.8
CC vs. AC + AA 6 1.29[0.95,1.76] 1.48[0.87,2.52] 0.101 45.7
C vs. A 6 1.17[1.02,1.34] 1.23[0.94,1.62] 0.011 66.1
Phet: P value for heterogeneity test.
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P value of the Egger’ test was not statistical significant
(t = 0.08, P = 0.940).
ERCC2 rs13181 SNP
The C allele frequency of ERCC2 rs13181 polymorphism
among the controls across different ethnicities ranged
from 0.08 to 0.34. The average C allele frequencies in
Asian and Caucasians populations were 19.4% and 34.0%,
respectively. There was almost no significant heterogeneity
in the analyses. The associations between rs13181 poly-
morphism and overall oral cancer risk were not statistically
significant (AC vs. AA: OR = 1.16, 95% CI = 0.96-1.40,
P = 0.171 for heterogeneity, I2 = 35.5%; CC vs. AA: OR =
1.71, 95% CI = 0.92-3.20, P = 0.044 for heterogeneity,
I2 = 56.1%; dominant model AC +CC vs. AA: OR = 1.24,
95%CI = 0.92–1.67, P = 0.045 for heterogeneity, I2 =
55.8%; recessive model CC vs. AC +AA: OR = 1.29, 95%
CI = 0.95–1.76, P = 0.101 for heterogeneity, I2 = 45.7%;
allele C vs. A: OR = 1.23, 95% CI = 0.94–1.62,
P = 0.011 for heterogeneity, I2 = 66.1%). The AIC values
of heterozygote model, variant homozygote model,
dominant model, recessive model and allelic model were
88.4, 104.6, 109.2, 87.2 and 118.0, showing that the re-
cessive model may be better than other models.
Stratified analyses were conducted for rs13181 poly-
morphism by ethnicity and tumor type (Table 3). In the
stratified analysis by ethnicity, no significant associations
were found among Asians. However, the subgroup ana-
lysis in Caucasians was not further performed because
there was only one study from Caucasians. In the strati-
fied analysis by tumor type, the risk of oral leukoplakia
was significant associated with rs13181 polymorphism
(AC vs. AA: OR = 1.28, 95% CI = 1.01-1.62, P = 0.546
for heterogeneity, I2 = 0.0%; CC vs. AA: OR = 1.94, 95%
CI = 0.99-3.79, P = 0.057 for heterogeneity, I2 = 60.1%;dominant model AC + CC vs. AA: OR = 1.35, 95% CI =
1.08–1.69, P = 0.303 for heterogeneity, I2 = 17.6%; allele
C vs. A: OR = 1.38, 95% CI = 1.04–1.82. P = 0.043 for
heterogeneity, I2 = 56.4%). There was no evidence for the
influence of rs13181 polymorphism on oral cancer suscep-
tibility. Figure 2 showed the meta-analysis results of the
association between ERCC2 rs13181 polymorphism and
oral cancer risk stratified by case type under the allele
model (C versus A) from random effects analysis. Figure 3
are the results of the association under the dominant
model (AC + CC versus AA) from fixed effects analysis.
No publication bias was indicated according to the
results of the inverted funnel plot, Begg’s test and Egger’s
test (data not shown).
Discussion
It is well known that individual susceptibility plays im-
portant role in the development of most cancers. Poly-
morphisms of genes involved in carcinogenesis may have
accounted for the susceptibility. Therefore, genetic suscep-
tibility, especially single nucleotide polymorphism (SNP),
to cancer has been a research focus in scientific commu-
nity. Understanding the genetic background and etiology
of oral cancer is essential for both the risk assessment and
findings of effective methods of prevention and treatment.
Recent genetic association studies on oral cancer risks
have focused on the effects of single nucleotide polymor-
phisms in Excision repair cross-complimenting group 2
(ERCC2) gene, namely Xeroderma pigmentosum D (XPD),
is an important DNA repair gene in nucleotide excision
repair (NER) pathway which could repair a wide variety
of structurally DNA lesions, including bulky adducts,
cross-links [17], oxidative DNA damage, thymidine dimers
[18] and alkylating damage [19]. SNPs in exons of DNA
repair genes may influence their protein activity, resulting
in differences of individual NER and DNA repair capacity
Table 3 Pooled ORs and 95% CIs for ERCC2 rs13181 polymorphism of stratified meta-analysis
Subgroup Genotype No of studies Test of association Test of heterogeneity
OR(95% CI) Z P-value Model χ2 P-value I2 (%)
Asian AC vs. AA 4 1.16[0.88,1.36] 0.83 0.405 F 5.81 0.121 48.3
CC vs. AA 4 1.33[0.59,3.01] 0.69 0.489 R 1.41 0.098 52.3
AC + CC vs. AA 4 1.13[0.75,1.71] 0.59 0.555 R 8.79 0.032 65.9
CC vs. AC + AA 4 1.08[0.74,1.56] 0.39 0.694 F 4.36 0.225 61.2
C vs. A 4 1.12[0.76,1.65] 0.56 0.576 R 10.90 0.012 72.5
Oral leukoplakia AC vs. AA 4 1.28[1.01,1.62] 2.01 0.045 F 2.13 0.546 0.0
CC vs. AA 4 1.94[0.99,3.79] 1.95 0.052 R 7.52 0.057 60.1
AC + CC vs. AA 4 1.35[1.08,1.69] 2.60 0.009 F 3.64 0.303 17.6
CC vs. AC + AA 4 1.67[0.90,3.13] 1.63 0.102 R 7.20 0.066 58.3
C vs. A 4 1.38[1.04,1.82] 2.26 0.024 R 6.88 0.043 56.4
Oral cancer AC vs. AA 4 1.10[0.73,1.65] 0.45 0.656 R 7.02 0.071 57.3
CC vs. AA 4 1.07[0.69,1.69] 0.31 0.758 F 5.26 0.154 43.0
AC + CC vs. AA 4 1.11[0.71,1.75] 0.46 0.643 R 9.29 0.026 67.7
CC vs. AC + AA 4 1.01[0.66,1.55] 0.06 0.951 F 3.13 0.371 4.3
C vs. A 4 1.09[0.73,1.64] 0.44 0.661 R 10.22 0.064 55.0
OR, odds ratio; vs, versus; R, random effect model; F, fixed effect model.
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The two SNPs analyzed in the present study were the
common SNPs in exons of ERCC2 gene. SNP rs1799793
is G > A substitution at ERCC2 codon 312 (exon 10,
Asp > Asn) and rs13181 is A > C substitution at ERCC2Figure 2 Meta-analysis of the association between ERCC2 rs13181 po
allele model (C versus A).codon 751 (exon 23, Lys > Gln). Growing number of
studies have been done to examine the relationship be-
tween these two SNPs and the risks of oral cancer [10-15].
However, the results are inconclusive. For the associa-
tions of ERCC2 polymorphisms with cancers, the negativelymorphism and oral cancer risk stratified by case type under the
Figure 3 Meta-analysis of the association between ERCC2 rs13181 polymorphism and oral cancer risk stratified by case type under the
dominant model (AC + CC versus AA).
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able studies now. To better understanding of the associ-
ation between these polymorphisms and oral cancer risk,
a meta-analysis with larger sample and subgroup analysis
is necessary. In the present meta-analysis, the statistical
power was increased by combining the results of six in-
cluded studies. The findings from this meta-analysis sug-
gested that there was a significant association between
rs13181 polymorphism in ERCC2 gene and risk of oral
cancer, which provided new evidence for the susceptibility
and etiology of oral cancer.
The current study is the first meta-analysis of the associ-
ation between ERCC2 rs1799793 and rs13181 polymor-
phisms with the risk of oral cancer. This meta-analysis
suggested that rs13181 (ERCC2 Lys751Gln) might be
associated with oral leukoplakia risk. There were studies
suggesting that SNP at amino acid 751 of ERCC2 may
play an important role in ERCC2 protein activity [20].
The ERCC2 751 polymorphism (rs13181) was associated
with higher levels of chromatic aberrations [21] and DNA
adducts levels [22]. It was reported that ERCC2 751
(rs13181) AC/CC genotypes were significantly defective
in NER [23] and had a modulating effect on DRC [24].
These results suggested that ERCC2 751 polymorphism
(rs13181) could result in a defect in NER and deficient
DRC that may be responsible for increased susceptibility
of oral cancer.Despite our efforts in performing a comprehensive ana-
lysis, some limitations exist in our meta-analysis. First, our
analysis used published international studies, which could
arise publication bias, although the results for publication
bias in our study were not statistically significant. Second,
lack of the original data of available studies limited our
further evaluation of potential interactions, such as age,
gender, family history, environmental factors and lifestyle.
Third, in stratified analysis we only studied the associ-
ation between ERCC2 rs13181 polymorphism and oral
cancer in Asians but could not evaluate the associ-
ation in Caucasians because of the limited studies from
Caucasian population. Until now, there was only one rele-
vant study found from Caucasians, and a precise estima-
tion on the association in Caucasians is difficult to make.
Therefore, more studies are needed to provide more
evidence on the association between ERCC2 polymor-
phisms and oral cancer risks in Caucasians and other
ethnic populations.
In conclusion, our meta-analysis supported that the
rs13181 polymorphism in ERCC2 gene more likely con-
tribute to the increasing risk of oral leukoplakia. Future
well-designed and larger population studies, especially
in Caucasians and other ethnic populations are of great
value to confirm these findings. Moreover, combination
of genetic factors together with environmental exposures
should also be considered.
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Rs13181 in ERCC2 gene might be associated with oral
leukoplakia risk.
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